The company has received follow-on investment and will begin further clinical trials in Germany soon.
Fertiligent, which has developed a device for the controlled release of sperm for in-vivo fertility treatments, has obtained EU CE Mark certification to market its Intra Uterine Insemination (IUI) device in Europe. The company also announced today that it had received additional financing from its existing investors, and that it would shortly begin further clinical trials at the Heinrich Heine University Medical Center in Dusseldorf, Germany.
Founded by general manager Ronnie Klein and Dr. Amnon Weichselbaum, Fertiligent recently graduated from the Yozmot HaEmek Technological Incubator. The company IUI device releases sperm in a controlled manner over several hours, instead of in a single shot used by current fertility treatments. The idea is to increase the number of opportunities for sperm to encounter the egg. The IUI also prevents the loss of sperm in the cervix by closing the cervix during treatment. This method mimics the natural controlled release of sperm as they pass through the cervix to the womb.
Fertiligent’s studies indicate that use of its IUI device has a high rate of success similar to that of in-vitro fertilization methods, which are considered complicated treatments used at a later stage. The cost of Fertiligent’s device is the same as sperm injections into the womb, which are considered the first stage of fertility treatments.
Published by Globes [online], Israel business news - www.globes.co.il - on March 28, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006